THU

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of:

Werner MEDERSKI et al.

Serial No.: 10/587,855

Group Art Unit: unknown

Filed: July 28, 2006

Examiner: unknown

For: UREA DERIVATIVES

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sirte A

1 33

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## Timing and Fees

$\boxtimes$	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:			
or start		within three months of the filing date of a national application other than a CPA under § 1.53(d);		
		within three months of the actual filing date of the national phase of a PCT application; OR		
t tebuga (		before the mailing of a first substantive office action (including after filing of ar RCE).		
. ,	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the specified in 37 C.F.R. § 1.97(b), but before the mailing date of:			
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and		

		is acco	ompanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR			
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:			
		a final	action under 37 C.F.R. § 1.113;			
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);			
,		OR a ı	notice of allowance under 37 C.F.R. § 1.311;			
	AND	is filed on or before payment of the issue fee; AND is accompanied by:				
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).			
Staten	nents U	nder 37	C.F.R. 1.97(e)			
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited	Materia	<u>ls</u>				
		ancest	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).			
		-	s of materials listed but not attached were cited in an international search dated			
		Not re	quired by 37 CFR § 1.98.			
	$\boxtimes$	Copies	s of the materials listed are attached.			

Non-English Language References							
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).					
		A foreign-language search report from a foreign patent office is provided, a pertinent parts are translated substantively below:					
		X =	document of particular relevance when it is taken alone				
		Y =	document of particular relevance when it is combined with another such document				
		A =	document defining the general state of the art				
		O =	non-written disclosure				
		<b>P</b> =	intercalated document				
		T =	document cited to understand the theory or principle underlying the invention				
		E =	patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date				
		D =	cited in the application				
		L =	cited for another reason				
		& =	publication of member of same patent family				
		Transl	ation of other relevant information on foreign search report				
		1					
Other ]	Informa	<u>ition</u>					
Payme	nt of Fe	es Due	(If Any):				
	A check for \$ covering the fee identified above is attached.						
	Please	charge	to Deposit Account No. 13-3402 \$ for the fee identified above.				

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelaro, Reg. No. 27,969 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

(705) 215 0110

Attorney Docket No.: MERCK-3199

Date: February 22, 2007

AJZ:rak

K:\Merck\3000 - 3999\3199\Information Disclosure Statement(lit).doc



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PTO			Complete if Known		
				Application Number	10/587,855	
INFO	RMATION	DIS	CLOSURE	Filing Date	July 28, 2006	
STAT	EMENT B	Y AF	PLICANT	First Named Inventor	Werner MEDERSKI et al.	
				Group Art Unit	unknown	
	(use as many she	ets as	necessary)	Examiner Name	unknown	
Sheet	1	of	1	Attorney Docket Number	MERCK-3199	

ere kormuneniment 3	en e	NON PATENT LITERATURE DOCUMENTS	· } * * #
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T_2
	C1	"Neutral Inhibitors of the Serine Protease Factor Xa," Bioorganic & Medicinal Chemistry Letters 11 (2001), pgs. 1801-1804.	
	C2	"Structure-Activity Relationships of Substituted," Bioorganic & Medicinal Chemistry Letters 13 (2003), pgs. 507-511.	
			_
	-		
		·	

Examiner Signature	Date Considered	
Signature	Considered	 

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.